Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Intravitreal REGN2176-3 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) (CAPELLA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02418754
Recruitment Status : Terminated (No additional efficacy seen with REGN2176-3 over aflibercept alone)
First Posted : April 16, 2015
Last Update Posted : February 20, 2017
Sponsor:
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : August 2016
  Estimated Study Completion Date : June 2017